Phase II clinical study evaluating the efficacy and safety of disitamab vedotin in patients (pts) with HER2-expressing urothelial carcinoma (RC48G001) Meeting Abstract
| Authors: | Koshkin, V. S.; Powles, T. B.; Iyer, G.; Loriot, Y.; Drakaki, A.; Martinez, I. D.; De Santis, M.; Retz, M.; Jain, R. K.; Chan, S.; Ichimaru, M.; Galsky, M. D. |
| Abstract Title: | Phase II clinical study evaluating the efficacy and safety of disitamab vedotin in patients (pts) with HER2-expressing urothelial carcinoma (RC48G001) |
| Meeting Title: | ESMO Congress 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 7 |
| Meeting Dates: | 2022 Sep 9-13 |
| Meeting Location: | Paris, France |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-09-01 |
| Start Page: | S1351 |
| Language: | English |
| ACCESSION: | WOS:000866211602329 |
| DOI: | 10.1016/j.annonc.2022.07.1938 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1779TiP -- Source: Wos |
